PDE5A and pulmonary arterial hypertension: For those SLE patients with worse functional classification, a combination of the immunosuppressive strategy with cyclophosphamide and prednisone plus PAH-specific therapy with a prostanoid, ERA, or PDE-5 inhibitor resulted in improved hemodynamic outcomes compared to immunosuppressive therapy alone [10].